论文部分内容阅读
目的研究磷酸西格列汀对2型糖尿病大鼠肝纤维化的影响。方法用高脂饮食加小剂量链脲佐菌素30 mg·kg~(-1)诱导建立2型糖尿病大鼠模型。建模后,实验组灌胃10 mg·kg~(-1)西格列汀;正常组和模型组灌胃等量0.9%Na Cl。12周后,以Masson染色法评估肝纤维化程度;以RT-PCR法测定转化生长因子β1(TGF-β1)、Smad3和Smad7的mRNA水平,以免疫印迹法测定肝组织、TGF-β1、Smad3、Smad7的蛋白表达。结果与模型组的TGF-β1值(1.15±0.23)相比,实验组的TGFβ1值为(0.80±0.13),实验组肝纤维化程度改善;较模型组的Smad3值为(1.02±0.08),实验组的Smad3值为(0.48±0.11),mRNA水平有所降低;较模型组的Smad7值为(0.57±0.14),实验组的Smad7值为(0.85±0.09),实验组mRNA有所升高,组间比较差异均有统计学意义(均P<0.01)。较模型组的肝组织TGF-β1值为(1.11±0.09)、Smad3蛋白含量(0.62±0.11)、Smad7蛋白含量为(0.90±0.07),实验组大鼠的肝组织TGF-β1值为(0.93±0.09)明显降低、Smad3蛋白含量为(0.51±0.09)明显降低、Smad7蛋白含量为(1.06±0.10)明显增加,组间比较差异均有统计学意义(P<0.01,P<0.05,P<0.05)。结论磷酸西格列汀改善糖尿病大鼠的肝纤维化,其机制可能与调节TGFβ/Smad信号通路有关。
Objective To investigate the effect of sitagliptin phosphate on hepatic fibrosis in type 2 diabetic rats. Methods A type 2 diabetic rat model was induced by high-fat diet plus low-dose streptozotocin 30 mg · kg -1. After modeling, the experimental group was fed with 10 mg · kg -1 sitagliptin. The rats in the normal group and model group were orally administered with 0.9% NaCl. After 12 weeks, the degree of hepatic fibrosis was evaluated by Masson staining. The mRNA levels of TGF-β1, Smad3 and Smad7 were determined by RT-PCR. The expression of TGF-β1, Smad3 , Smad7 protein expression. Results Compared with TGF-β1 (1.15 ± 0.23) in TGF-β1 group, the TGFβ1 level in the experimental group was (0.80 ± 0.13), and the degree of hepatic fibrosis in the experimental group was improved. Compared with the model group, the Smad3 value was (1.02 ± 0.08) The Smad3 in the experimental group was (0.48 ± 0.11) and the mRNA level was decreased. The Smad7 in the experimental group was (0.57 ± 0.14), the Smad7 in the experimental group was (0.85 ± 0.09) , There was significant difference between the two groups (all P <0.01). Compared with model group, the values of TGF-β1 in hepatic tissue were (1.11 ± 0.09), Smad3 protein content (0.62 ± 0.11) and Smad7 protein content (0.90 ± 0.07) ± 0.09), the content of Smad3 protein was significantly decreased (0.51 ± 0.09) and the content of Smad7 protein was significantly increased (1.06 ± 0.10, P <0.01, P <0.05, P < 0.05). Conclusions Sitagliptin phosphate can improve hepatic fibrosis in diabetic rats. The mechanism may be related to the regulation of TGFβ / Smad signaling pathway.